Table 1.
Demographic, virological, serological, and clinical characteristics of SARS‐CoV‐2‐infected patients.
| SARS‐CoV‐2‐vaccinated patients (72/103, 70%) | SARS‐CoV‐2‐unvaccinated patients (31/103, 30%) | ||||
|---|---|---|---|---|---|
| Parameters | Median (IQR 25%–75%) | n (%) | Median (IQR 25%–75%) | n (%) | p |
| Sex assigned at birth | |||||
| Male | – | 36 (50) | – | 14 (45) | .643 |
| Female | 36 (50) | 17 (55) | .435 | ||
| Age (years) | 66 (58–75) | – | 57 (46–66) | – | .004 |
| Charlson Comorbidity Index* | 3 (3–4) | – | 2 (1–3) | – | .006 |
| Anti‐Spike (S) antibody levels at T0a | |||||
| Undetectable (<33.8 BAU/mL) | – | 13 (20.3) | – | 26 (83.9) | <.0001 |
| Low (33.8–400 BAU/mL) | – | 30 (46.9) | – | 3 (9.7) | .0004 |
| High (>400 BAU/mL) | – | 21 (32.8) | – | 2 (6.4) | .0051 |
| SARS‐CoV‐2‐RNA levels at T1b | |||||
| High (<34 C t) | – | 19 (32) | – | 15 (58) | .025 |
| Low (≥34 C t) | – | 23 (39) | – | 11 (42) | .796 |
| Undetected (>45 C t) | – | 17 (29) | – | 0 (0) | .002 |
Note: Data were analyzed using “N‐1” χ 2 test and p < .05 were considered statistically significant.
Abbreviations: BAU, binding antibody units; IQR, interquartile range; mAbs, monoclonal antibodies; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
a
Before mAbs therapy. Data available for 64 and 31 vaccinated and unvaccinated patients, respectively.
b
12 days after mAbs therapy. Data available for 59 and 26 vaccinated and unvaccinated patients, respectively.
*The Charlson Comorbidity Index predicts the mortality for a patient who may have a range of concurrent conditions. 16